Skip to main content
. 2019 Oct 3;105(7):1868–1878. doi: 10.3324/haematol.2019.223933

Figure 2.

Figure 2

The impact of ecto-CRT on the activation and cytotoxic potential of natural killer cells in acute myeloid leukemia patients. (A, B) The percentage of IFN-γ-and degranulating (CD107a+/GZMB+) CD45+CD3CD56+ natural killer (NK) cells upon PMA + Ionomycin or K562 cell line stimulation in 17 CRTLo and 18 CRTHi acute myeloid leukemia (AML) patients prior to the induction chemotherapy (A) or in 12 CRTLo and 12 CRTHi AML patiens after the restoration of normal hematopoiesis (B). Patient samples were analyzed by flow cytometry. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum; ns: not significant. (C) Cytotoxic potential of NK cells isolated from AML patients before the initiation of chemotherapy (Prior, n=10) versus upon the restoration of normal hematopoiesis (Recovery, n=10). Purified NK cells were tested for their ability to kill target K562 cell line at two different effector:target cell ratios (5:1 and 10:1) and the viability of K562 cells was determined by flow cytometry after 4 hours (h). (D, E) Cytotoxic potential of NK cells isolated from five CRTHi and 5 CRTLo AML patients before the initiation of chemotherapy (D) or upon the restoration of normal hematopoiesis (E). Purified NK cells were tested for their ability to kill target K562 cell line at effector:target cell ratio 5:1 and the percentage of dead (AnnV+DAPI+) K562 cells was determined by flow cytometry after 4 h. The representative dot plots of NK cell cytotoxicity assay showing the viability of target K562 cells in CRTHi versus CRTLo AML patients before the initiation of chemotherapy (D) or upon the restoration of normal hematopoiesis (E) are shown. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum; ns: not significant. CRT: calreticulin.